DRTSAlpha Tau Medical Ltd.

$14.43+253% 1Y

Price

+253%1Y

End-of-day closes, not the intraday tick.

RyuScore

Weak, higher than 3% of companies
7/100
Seven criteria, weighted: see how it is built

The five questions

2 of 5 available

Only two of the five can be answered for DRTS today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Watch
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Mixed
What they do

We are a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Our proprietary Alpha DaRT® technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation’s limited range.

In the company’s own words · 20-F filed Mar 9, 2026 · SEC EDGAR

P/En/a
Market value$1.01B
1 year+253%
5 years+47%

Charts

As reported to the SEC, without any scoring.